Real-World Evidence: A Primer

被引:87
作者
Dang, Amit [1 ]
机构
[1] MarksMan Healthcare Commun, J1309, Amethyst Tower, Hyderabad 500091, Telangana, India
关键词
TRIALS;
D O I
10.1007/s40290-022-00456-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Real-world evidence (RWE) is clinical evidence on a medical product's safety and efficacy that is generated using real-world data (RWD) resulting from routine healthcare delivery. There are several sources of RWD, including electronic health records (EHRs), registries, claims/billing data, and patient-generated data, as well as those from mobile health applications and wearable devices. Real-world data from these sources can be collected and analysed through different study designs such as prospective and retrospective cohort studies, case-control studies, and pragmatic clinical trials. Real-world evidence in the form of post-marketing surveillance has been extensively used to generate pharmacovigilance data. Of late, it has been realised that, apart from safety, RWE has additional applications in different stages of the drug approval cycle, and can be used to optimize the design of randomised controlled trials (RCTs). There has been an increasing awareness and acceptance of RWE from different stakeholders, including physicians, pharmaceutical companies, payers, regulators, and patients. Several regulatory authorities have also created frameworks and guidelines for efficient harnessing of RWE while acknowledging several challenges in RWD collection and analysis. The purpose of this review is to offer an outline of the current information on RWE, its advantages and disadvantages, as well as the associated challenges and ways to overcome them, while also throwing some light on the future of RWE.
引用
收藏
页码:25 / 36
页数:12
相关论文
共 89 条
  • [1] New oral anticoagulants-TURKey (NOAC-TURK): Multicenter cross-sectional study
    Altay, Servet
    Yildirimturk, Ozlem
    Cakmak, Huseyin Altug
    Askin, Lutfu
    Sinan, Umit Yasar
    Besli, Feyzullah
    Gedikli, Omer
    Tok, Ozge Ozden
    Karadeniz, Fatma Ozpamuk
    Unlu, Serkan
    Yanik, Ahmet
    Ucar, Fatih Mehmet
    Duman, Hakan
    Canpolat, Ugur
    Koroglu, Bayram
    Yayla, Cagri
    Ozcan, Kazim Serhan
    Velibey, Yalcin
    Gulel, Okan
    Kalkan, Mehmet Emin
    Karaca, Gurkan
    Akboga, Mehmet Kadri
    Akdag, Serkan
    Eren, Mehmet
    Sahin, Mahmut
    Pehlivanoglu, Seckin
    [J]. ANATOLIAN JOURNAL OF CARDIOLOGY, 2017, 17 (05) : 353 - 361
  • [2] [Anonymous], 2021, EUROPEAN CYSTIC FIBR
  • [3] [Anonymous], CLIN ONCOLOGY N 0918
  • [4] [Anonymous], 2018, SUBMITTING DOCUMENTS
  • [5] [Anonymous], 2018, About Us
  • [6] Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial
    Aoun, Mabel
    Sleilaty, Ghassan
    Boueri, Celine
    Younes, Eliane
    Gabriel, Kim
    Kahwaji, Reine-Marie
    Hilal, Najla
    Hawi, Jenny
    Araman, Rita
    Chelala, Dania
    Beaini, Chadia
    [J]. BMC NEPHROLOGY, 2022, 23 (01)
  • [7] arbormetrix, MICHIGAN BARIATRIC S
  • [8] Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value
    Arlett, Peter
    Kjaer, Jesper
    Broich, Karl
    Cooke, Emer
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) : 21 - 23
  • [9] Barham, 2015, REAL WORLD EVIDENCE
  • [10] Real-World Data: An Unrealized Opportunity in Global Health?
    Barrett, Jeffrey S.
    Heaton, Penny M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (01) : 57 - 59